The AP4S1 Knockout HT29 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population targeting the AP4S1 gene in the human colorectal adenocarcinoma cell line HT29. This loss-of-function model enables investigation of AP4S1, encoding the sigma4 subunit of adaptor protein complex 4 (AP-4). CRISPR/Cas9-mediated gene disruption generates a heterogeneous pool of cells with various edits, avoiding clonal selection and preserving cellular heterogeneity for bulk population studies, high-throughput screening, and phenotypic analysis.
HT29 cells are a widely used intestinal epithelial tumor model originally derived from a primary colon adenocarcinoma of a 44-year-old female. These cells maintain an epithelial morphology and express differentiation markers characteristic of intestinal epithelium, making them a standard system for cancer biology, drug transport, and intestinal physiology research. The adherent growth and robust proliferation of HT29 cells facilitate a broad range of experimental protocols, including immunofluorescence microscopy, flow cytometry, and biochemical assays.
AP4S1 encodes the sigma4 subunit, an essential component of the heterotetrameric AP-4 complex (comprising AP4E1, AP4B1, AP4M1, and AP4S1). AP-4 is recruited to the trans-Golgi network by the small GTPase ARF1, where it selects transmembrane cargo proteins for vesicular transport to late endosomes and lysosomes. Key cargo molecules include the amyloid precursor protein (APP) and the autophagy-related protein ATG9A. AP4S1 transcription is regulated by the RE1-silencing transcription factor (REST). Disruption of AP4S1 impairs AP-4 complex formation and abolishes its sorting function, leading to defective lysosomal targeting and dysregulated autophagy. Consequently, AP4S1 knockout models are instrumental for dissecting the molecular mechanisms of AP-4-dependent trafficking, cargo recognition, and lysosomal biogenesis.
In the context of HT29 colorectal adenocarcinoma cells, AP4S1 knockout creates a unique model to study how AP-4-mediated trafficking intersects with cancer cell biology. HT29 cells possess active endosomal and autophagic pathways, and loss of AP4S1 may perturb lysosomal enzyme delivery and autophagy flux, potentially affecting tumor cell proliferation, migration, or drug sensitivity. This model allows researchers to explore the functional consequences of AP-4 dysfunction in an epithelial tumor background, bridging the gap between basic cell biology and the pathologies associated with AP-4 deficiency syndrome, such as hereditary spastic paraplegia type 47 and neurodevelopmental disorders.
Typical applications include mechanistic studies of intracellular trafficking, investigation of AP-4 deficiency syndrome pathogenesis, screening of small molecules that modulate lysosomal function or autophagy, and analysis of colorectal cancer cell behavior. Researchers can employ techniques such as Western blotting to confirm AP4S1 depletion, immunofluorescence microscopy to visualize AP-4 complex mislocalization, RT-qPCR for transcriptional assessment, flow cytometry to quantify cell surface accumulation of mis-sorted cargo, and autophagy flux assays using LC3 turnover. Lysosomal enzyme activity assays and migration/invasion assays further extend the utility of this model. For additional technical details or customized solutions, please contact Ascent Research.
